This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Article
Lauren Colbert
The University of Texas MD Anderson Cancer Center
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Human papillomavirus (HPV) infection causes 600,000 new cancers worldwide each year. HPV-related cancers express the oncogenic proteins E6 and E7, which could serve as tumor-specific antigens. It is not known whether immunity to E6 and E7 evolves during chemoradiotherapy (CRT) or affects survival. We used functional T-cell assays to identify candidate HPV-specific T-cells and T- cell motifs common across 86 patients with HPV-related cancers. These HPV-specific clones and E7-related motifs expanded over the course of treatment, whereas non-HPV-specific T-cells did not. In HPV16+ patients, improved recurrence-free survival was associated with this HPV-responsive T-cell expansion during CRT.
Keywords
Human papillomavirus (HPV), tumor-specific antigens, chemoradiotherapy, T-cell assays
Figure 1
Figure 2
Figure 3
Figure 4
Yes there is potential Competing Interest. ACK holds stock in Aravive, Inc., and also serves as a consultant. PD reports personal fees from Adlai Nortye, personal fees from MD Anderson Cancer Center Madrid Spain, outside the submitted work.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementalFigures.docx
- SupplementalTable1.xlsx
Supplemental Table 1
- SupplementalTable2.csv
Supplemental Table 2
- SupplementalTable3.csv
Supplemental Table 3
- SupplementalTable4.xlsx
Supplemental Table 4
- SupplementalTable5.xlsx
Supplemental Table 5
- SupplementalTable6.pdf
Supplemental Table 6
- SupplementalTable7.xlsx
Supplemental Table 7
- SupplementalTable8.xlsx
Supplemental Table 8
- SupplementalTable9.xlsx
Supplemental Table 9
- SupplementalTable10.pdf
Supplemental Table 10
- SupplementalTable11.pdf
Supplemental Table 11
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 16 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Article
Lauren Colbert
The University of Texas MD Anderson Cancer Center
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 16 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Human papillomavirus (HPV) infection causes 600,000 new cancers worldwide each year. HPV-related cancers express the oncogenic proteins E6 and E7, which could serve as tumor-specific antigens. It is not known whether immunity to E6 and E7 evolves during chemoradiotherapy (CRT) or affects survival. We used functional T-cell assays to identify candidate HPV-specific T-cells and T- cell motifs common across 86 patients with HPV-related cancers. These HPV-specific clones and E7-related motifs expanded over the course of treatment, whereas non-HPV-specific T-cells did not. In HPV16+ patients, improved recurrence-free survival was associated with this HPV-responsive T-cell expansion during CRT.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...